Most prevalent side effects of aromatase inhibitors in the treatment of hormone-positive breast cancer: a scoping review
DOI:
https://doi.org/10.29289/2594539420230033Palavras-chave:
Aromatase inhibitors, breast neoplasm, estrogen receptor, side effectsResumo
-
ABSTRACT: Hormone-positive breast cancer is the most commonly diagnosed breast neoplasm among postmenopausal women and is strongly associated with the effects of estrogens on hormone receptors of breast cells. Aromatase inhibitors are especially prescribed for treatment, and are effective to reduce mortality rates and the development of a new contralateral breast tumor. However, even with the proven efficacy and safety in use of these medications, approximately 50% of the patients abandon treatment before the prescribed period due to their side effects. The study was carried out with the objective of mapping what national and international literature declare about the most prevalent side effects caused by aromatase inhibitors in the treatment of women with hormone-positive breast cancer. We used the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Review to elaborate this review. The methodology of choice was a scoping review aiming at synthetizing relevant information in an objective and clear manner about this drug class that is so common in breast cancer therapy, mainly benefitting women who are users of such drugs. According to the literature, reduced bone mineral density, arthralgia, hot flushes and dryness of the vaginal mucosa are the most reported symptoms, directly related with the absence of estrogen action on the body. These effects have a direct repercussion on the quality of life and on the discontinuation of treatment, leading to reduced functionality and high mortality rates.
Downloads
Referências
1. Borrie AE, Kim RB. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opin Drug Metab Toxicol. 2017;13(2):149-56. https://doi.org/10.1080/17425255.2017.1234605
2. Artigalás OAP. Estudo farmacogenético e farmacoeconômico em pacientes brasileiras portadoras de câncer de mama tratadas com inibidores da aromatase [tese]. Porto Alegre: Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul; 2015.
3. Underwood EA, Jerzak KJ, Lebovic G, Rochon PA, Elser C, Pritchard KI, et al. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Support Care Cancer. 2019;27(8):3035-43. https://doi.org/10.1007/s00520-018-4603-5
4. Gonzaga LA, Paulo TRS, Viezel J, Vanzella LM, Freitas Jr IF, Vanderlei LCM. Changes in cardiac autonomic modulation in women with breast cancer using aromatase inhibitors and the relation with biochemical variables. Arq Bras Cardiol. 2019;112(5):555-63. https://doi.org/10.5935/abc.20190036
5. Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;12:713700. https://doi.org/10.3389/fendo.2021.713700
6. Abubakar MB, Wei K, Gan S. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenet Genomics. 2014;24(12):575-81. https://doi.org/10.1097/FPC.0000000000000092
7. Bhave MA, Speth KA, Kidwell KM, Lyden A, Alsamarraie C, Murphy SL, et al. Effect of aromatase inhibitor therapy on sleep and activity patterns in early-stage breast cancer. Clin Breast Cancer. 2018;18(2):168-174.e2. https://doi.org/10.1016/j.clbc.2017.12.012
8. Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer. 2014;21(1):R31-49. https://doi.org/10.1530/ERC-13-0269
9. Nemitz N, Kurmann PT, Van Linthoudt D. Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor. Praxis (Bern 1994). 2008;97(3):137-41. https://doi.org/10.1024/1661-8157.97.3.137
10. Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21(16):5625. https://doi.org/10.3390/ijms21165625
11. Bundred NJ. Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol. 2009;21(1):60-7. https://doi.org/10.1097/GCO.0b013e32831da80e
12. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107(2):167-80. https://doi.org/10.1007/s10549-007-9548-1
13. Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, et al. CYP11A1 expression in bone is associated with aromatase inhibitor related bone loss. J Mol Endocrinol. 2015;55(1):69-79. https://doi.org/10.1530/JME-15-0079
14. Scarpa R, Atteno M, Peluso R, Costa L, Padula S, Di Minno D, et al. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. J Clin Rheumatol. 2011;17(4):169-72. https://doi.org/10.1097/RHU.0b013e31821bfc48
15. Gallicchio L, Macdonald R, Wood B, Rushovich E, Helzlsouer KJ. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2011;130(2):569-77. https://doi.org/10.1007/s10549-011-1611-2
16. Krásenská M. Treatment with aromatase inhibitors in postmenopausal women with breast cancer and the possibility of influencing side effects. Klin Onkol. 2016;29(Suppl 3):S39-49. https://doi.org/10.14735/amko20163S39
17. Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin. 2006;22(8):1609-21. https://doi.org/10.1185/030079906X115667
18. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer. 2001;37(12):1510-3. https://doi.org/10.1016/s0959-8049(01)00155-1
19. Kwan KW, Chlebowski RT. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer. 2009;9(4):219-24. https://doi.org/10.3816/CBC.2009.n.037
20. Bicer T, Imamoglu GI, Dogan, AS, Avarisli NA, Kabatas N, Bicer BK, et al. The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer. Int Ophthalmol. 2020;40(8):2077-83. https://doi.org/10.1007/s10792-020-01384-7
21. Phillips KA, Ribi K, Fischer R. Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res. 2011;13(1):203. https://doi.org/10.1186/bcr2806
22. Rocha-Cadman X, Massie MJ, Du Hamel K. Aromatase inhibitors and mood disturbances. Palliat Support Care. 2012;10(3):225-7. https://doi.org/10.1017/S1478951512000636
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Giulia Rafaela Zuffo, Kethilyn Aparecida Ricardo, Heloisa Comnisky, Alexandra Ingrid dos Santos Czepula
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
